- The failed proposed recommendations SCCR/30
- Summary by the Chair, of SCCR 30
- SCCR 30: Resale right proposal on the table?
- KEI intervention on education exceptions in SCCR 30
- SCCR30: United States- Preservation - Copyright limitations and exceptions for libraries and archives
- KEI intervention on preservation exceptions at WIPO SCCR 30
- Chairman's non-paper on copyright exceptions for libraries, archives
- SCCR30 (Day 4): Discussion heats up on discussions on copyright limitations and exceptions for libraries and archives
- Iran’s Statement on the limitations and exceptions at WIPO SCCR 30
- SCCR 30 End of Session on the Broadcasters’ Treaty: Snail pace to -almost- reach consensus
WIPO CDIP 15: Statement of Brazil on evaluation of the Project on Open Collaborative Projects and IP-Based ModelsSubmitted by thiru on 21. April 2015 - 4:00
On Tuesday, 21 April 2015, the 15th session of the World Intellectual Property Organization's (WIPO) Committee on Development and Intellectual Property (CDIP) considered the Evaluation Report for the Project on Open Collaborative Projects and IP-Based Models (CDIP/15/3). This project on open collaborate development models is based on Recommendation 36 of the WIPO which states,
Governments can ration access to cancer drugs, or break patent monopolies. Why is rationing so popular?Submitted by KEI Staff on 20. April 2015 - 17:02
The California Assembly Health Committee has published an analysis of AB463, the Pharmaceutical Cost Transparency Act of 2015. The bill will be marked up by the committee on Tuesday (April 21). The analysis was written by Dharia McGrew. It recommends three amendments to the bill, and provides a discussion of the benefits of the required disclosures, with context, and describes the support and opposition. The staff report is attached, and below is a list of 33 groups supporting and 22 opposing the bill.
Knowledge Ecology International (KEI) will present the following statement on 20 April 2015 to the Open Session of the 20th Expert Committee on the Selection and Use of Essential Medicines.
Statement of Knowledge Ecology International: WHO 20th Expert Committee on the Selection and Use of Essential Medicines, with specific focus on expanding access to new cancer drugs, when available at affordable prices
20 April 2015
Dear members of the WHO Expert Committee and the WHO secretariat,
State of California considers AB463, a bill to require disclosure of drug development costs, and more economic dataSubmitted by James Love on 17. April 2015 - 6:35
This is a bill that will see legislative action next week in California, and the bill has some momentum. This is the first time I have seen any government make an effort to have useful data on the economics drug drug development and pricing, and it provides a model that other governments may want to built upon.
A mark-up on the bill has been scheduled for Tuesday, April 21, 2015, in the Assembly Health Committee.
BILL NUMBER: AB 463
INTRODUCED BILL TEXT
INTRODUCED BY Assembly Member Chiu
FEBRUARY 23, 2015
This from the Wikileaks Sony Archive:
An email from Keith Weaver, the "Executive Vice President, Worldwide Government Affairs at Sony Pictures Entertainment, provide an illustration the practical art of doing "Government Affairs," meeting "goals" for fundraisers, trying to avoid making "personal" contributions, and wondering if the donations were to much focused on another company's purchase of policy" "smells a little bit like a Disney play regarding corp. tax reform".
From: Weaver, Keith
Sent: Tuesday, August 26, 2014 5:23 PM
To: Weil, Leah
Sony referred to "WIPO treaty for blind as "stalking horse" to "denigrate the rights of copyright owners"Submitted by KEI Staff on 16. April 2015 - 13:32
In the new Wikileaks archives of leaked Sony documents (Link here), there is a memo (https://wikileaks.org/sony/docs/05/docs/DECE/DECE%20CP1%20-%20ss.doc.pdf), which describes Sony Pictures Entertainment (SPE) concern over the proposed WIPO treaty for copyright exceptions for persons who are blind or have other disabilities. The memo, undated in the Wikileaks archives, but probably written in 2009, included the following passages:
The following attached letter [PDF ], from KEI and Public Citizen, asks the NIH to impose certain conditions on an exclusive license on NIH owned patents for a drug to treat the hepatitis C virus (HCV). The NIH wants to license the patents to Virotas Biopharmaceuticals, LLC, a company having a place of business in California. Other than the patents involved, the NIH requires people to sign a non-disclosure to know more about the deal.
TRIPS Council (October 2014): India calls for de-linkage and innovation inducement prizes at WTO discussions on IP & innovationSubmitted by thiru on 30. March 2015 - 3:25
In advance of the World Trade Organization's October 2014 session of the TRIPS Council, the European Union, Switzerland and the United States made a written request to the TRIPS Council to discuss "Intellectual Property and Innovation: Promoting Awareness; Case Studies" under agenda item 12. This marked the 7th time that the United States tabled an item to the TRIPS Council relating to intellectual property or innovation.
In the context of these October 2014 discussions of Intellectual Property and Innovation, the Government of India delivered the following intervention asserting that,
Twenty groups write Congress, no fast track without public access to trade agreement negotiating textsSubmitted by James Love on 20. March 2015 - 15:09
Twenty groups, including KEI, have written Congress, asking the Congress to provide public access to draft trade agreement texts and U.S. proposals throughout negotiations, and to specific that only agreements developed through such processes should obtain any expedited congressional consideration.
Among other things, the groups said:
On March 18, 2015, KEI, KEI Europe, and Essential Inventions submitted proposals for global voluntary licences for all patents necessary for hepatitis C (HCV) medicines to five drug companies -- AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck.
HRC28: Statement of the European Union- Cultural Rights (Response to SR Report on Copyright and Right to Science and Culture)Submitted by thiru on 12. March 2015 - 10:56
On Wednesday, 11 March 2015, Oliver Hall-Allen, First Counsellor, Delegation of the European Union to the United Nations Office in Geneva delivered the following statement in response to the presentation of the Special Rapporteur in the Field of Cultural Rights (Farida Shaheed) on her Report on Copyright policy and the right to science and culture (A/HRC/28/57).
Oliver Hall-Allen (blue tie, white shirt), First Counsellor, Delegation of the European Union to the United Nations Office in Geneva
HRC28: Statement of the United States of America - Cultural Rights (Response to SR Report on Copyright and Right to Culture)Submitted by thiru on 11. March 2015 - 18:19
On Wednesday, 11 March 2015, Ambassador Keith Harper, U.S. Representative to the Human Rights Council, delivered the following statement to the 28th Session of the Human Rights Council on the topic of cultural rights.
HRC28: Statement by Farida Shaheed, Special Rapporteur, on Copyright policy and the right to science and cultureSubmitted by thiru on 11. March 2015 - 5:45
On Wednesday, 11 March 2015, Farida Shaheed, the United Nations Special Rapporteur in the field of cultural rights presented her seminal report on Copyright policy and the right to science and culture (A/HRC/28/57) at the 28th session of the Human Rights Council in Geneva.
Highlights from the report's recommendations include the following:
WTO at 20: Symposium on the TRIPS Agreement for TRIPS Council Members and Observers (26 February 2015)Submitted by thiru on 4. March 2015 - 11:22
As part of the World Trade Organization's (WTO) technical assistance and capacity building program, on Thursday, 26 February 2015, the WTO Secretariat convened Symposium on the TRIPS Agreement for TRIPS Council Members and Observers which brought together negotiators from the 1986–94 Uruguay Round to discuss how the Round introduced intellectual property norms into the architecture of the multilateral trading system. In addition, other experts were brought in to discuss what has happened since the introduction of the TRIPS Agreement, and what augurs for the future.